

Time	Ticker	Bond	Amt Out (MM)	Maturity	Upfront cash	Consent fee/ Incentive cash	New Bond	New Maturity	Type	Remarks
1/13/2022	YUZHOU	YUZHOU 8.65 2022 YUZHOU 6 2022	242 340	1/23/2022	5pts	1pt	95pts	1/21/2023	Exchange Offer & consent solicitation	- Minimum accpetance amount: 90% in principal amount of each of the original bonds - Deadline: 19 Jan 2022
1/7/2022	SHXREG	SHXREG 12.5 2022	275	1/23/2022	Series A 5pts Series B 0	0	Series A 95pts Series B 100pts	1/17/2023	Exchange Offer & consent solicitation	Series A - Secured by 3 onshore projects as collateral (LTV ratio not exceeding 68%) - Personal Guarantee of Mr. Chen Guoxiang (controlling shareholder) - max acceptance amount: 164mn - new bond coupon: 13% - deadline: 14 Jan 2022 Series B - No accrued interest - max acceptance amount: 150mn - new bond coupon: 13% - deadline: 14 Jan 2022
1/6/2022	DAFAPG 2	DAFAPG 9.95 2022	185	1/18/2022	4pts	1pt	96pts	6/30/2022	Exchange Offer & consent solicitation	- minimum accpetance amount: 90% (Company waived the minimum acceptance amount on 14 Jan 2022) - 78.12% valid tenders of existing notes (USD 40.4mn remain outstanding) - new coupon rate: 12.50%
1/7/2022 1/7/2022		DAFAPG 12.375 2022 DAFAPG 13.5 2023	360 100	7/30/2022 4/28/2023		0.2pts			Consent solicitation	- minimum accpetance amount: 50% (Received Requisite Consents on 14 Jan 2022)
12/22/2021	SUNKWP	SUNKWP 12.75 2022	185	1/21/2022			100pts; 139.2mn new bond + 45.8mn old bond	1/2/2023	Excahnge Offer & Expiration Deadline Extension	- 75.24% valid tenders of existing notes received - new coupon rate: 13.5%
12/21/2021	RISSUN	RISSUN 8.95 2022	292	1/18/2022	5pts	2.5pts (Early); 0.5pts (Base)	95pts; Up to 540 + Remainder	7/14/2024 (540mm) 1/13/2023 (Remainder)	Exchange Offer & consent solicitation	- New notes amortizing schedule: 20% in Year 1; 40% in Year 2, 40% in Year 2.5 - New Notes interest coupon: 9.5% - Specified Asset Sales Undertaking
		RISSUN 8 2022	488	4/24/2022	- 12 - 22					 Negative pledge on this specified assets. over 75% valid tenders of existing notes received. Risesun will proceed the scheme to exchange all bonds
12/21/2021	GWTH	GWTH 12.95 2022	122	11/7/2023		0.4pts+0.1pts	445	3/31/2025	Exchange Offer & RSA	- Over 80% valid tenders of existing notes, exceeding 75% minimum acceptance amount - 5%, 15%, 10%, 10% and 55% on or before 9 months, 15 months, 21 months, 27 months and
		GWTH 14.25 2023 GWTH 16 2023	178 145	9/1/2023 3/14/2022	5pts					year 3 maturity.
1/12/2022	GZRFPR	GZRFPR 5.75 2022	725		Option A 83%	Option A 0	Option A N/A		- new coupon rate: 10% Option A (71.69% tendered option) - cash principal repayment: USD 79,999,550 - Est upfront cash: USD 18.8 per notional USD 100 - proration factor: 18.57%	
				1/13/2022	Option B 50%	0.1pts	Option B 50%	Option B 7/31/2022	Tender offer	Option B (24.19% tendered option) - cash principal repayment: USD 19,984,000 - Est upfront cash: USD 3.5 per notional USD 100 - proration factor: 7.1157% USD 608.6mn notes remain outstanding
12/7/2021	CSCHCN	CSCHCN 11.5 2022 CSCHCN 10.875 2022	348 346	12/2/2022 6/26/2022					Bondholders Identification	CSCHCN11.5%'22 and 10.875%'22
11/25/2021	KAISAG	KAISAG 6.5 2021	400	7/12/2021	2.5pts		100pts	6/6/2023	Exchange Offer & consent solicitation	- Minimum accpetance amount: 90% in principal amount of each of the original bonds - Expired due to valid tenders of the existing notes of less than the minimum acceptance amount - in discussion to reach solution
11/20/2021	CAPG	CLINICHI E 2 2022	200	11/1/2022					Financial Advisor	Admiralty Harbour Capital and Linklaters
11/1/2021	SUNSHI	SUNSHI 5.3 2022 SUNSHI 10.25 2022 SUNSHI 10 2023	200 300 247	11/1/2022 3/18/2022 12/2/2023	2.5pts	0.5pts	100pts	9/15/2022	Exchange Offer & consent solicitation	Valid tenders of the existing notes were over minimum acceptance amount of 85% for all three bonds
		SUNSHI 9.25 2023 SUNSHI 8.25 2023 SUNSHI 7.5 2024 SUNSHI 7.875 2024 SUNSHI 7.5 2025	300 296 357 280 264	4/15/2023 11/25/2023 4/15/2024 4/9/2024 2/17/2025		0.5pts			Consent solicitation	In order to avoid cross default, the company is seeking the consents solicitation to amend the indentures of the rest of the 5 offshore USD bonds
10/22/2021									Bondholders Identification	All outstanding bonds and company said to improve communication
9/13/2021		MOLAND 12.85 2021	250	10/25/2021	35pts	0.1pts	65pts	1/25/2022	Consent solicitation Financial Advisor	Consent terminated and debt defaulted Admiralty Harbour Capital & Houlihan Lokey
7/12/2021									Financial Advisor	Admiralty Harbour Capital

Fixed Income Department

Tel: 852 3761 8867/852 3657 6291

fis@cmbi.com.hk

CMB International Securities Limited ("CMBIS") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Author Certification

The author who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the author covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that author in this report.

Besides, the author confirms that neither the author nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIS does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIS recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIS, solely for the purpose of supplying information to the clients of CMBIS and/or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIS nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIS has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIS provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIS may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIS may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIS may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIS does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIS may have a conflict of interest that could affect the objectivity of this report and CMBIS will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIS.

Additional information on recommended securities is available upon request.

Disclaimer

CMBIS or its affiliate(s) have investment banking relationship with the issuers covered in this report in preceding 12 months.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time)("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc...) of the Order, and may not be provided to any other person without the prior written consent of CMBIS.

For recipients of this document in the United States

CMBIS is not a registered broker-dealer in the United States. As a result, CMBIS is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a

copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.